SyntheMed’s REPEL-CV Approved by Australian Regulators
REPEL-CV, an anti-adhesion barrier developed by biomaterials company SyntheMed, has received approval by the Australian Therapeutic Goods Administration for use in open-heart surgery.
feature1
BioNeutral to Expand Into Asia
BioNeutral Group, a developer of chemical-based technology, announced that they will form a new wholly owned subsidiary in Hong Kong to commercialize their proprietary chemical formulations throughout Asia.
Bioject Signs With U.S. Navy for Malaria Vaccine
Bioject Medical Technologies, a developer of needle-free injection systems, has signed a cooperative R&D agreement with the U.S. Navy to use Bioject’s technology in a malaria vaccine the Navy is developing.
Provenge Extends Life of Prostate Cancer Patients, Study Finds
Researchers found that Dendreon’s immunotherapy drug Provenge prolonged the lives of advanced prostate cancer patients by an average of 4.1 months compared to a placebo.
Microline PENTAX Acquires Starion Instruments
Two strong players in the surgical-instrument field have joined forces. Microline PENTAX, a leading manufacturer of reposable surgical instruments for laparoscopic procedures, has acquired California-based Starion Instruments, a developer of instruments to arrest bleeding during surgical procedures.
Isto Gets Go-Ahead for Clinical Study of NuQu
ISTO Technologies has received FDA approval to begin a Phase I clinical study for NuQu, an injectable formulation of juvenile cartilage cells designed to treat chronic back pain caused by degenerative disc disease.
Major Milestone for Sunshine Heart
Sunshine Heart, a global company that develops cardiac assist devices, has successfully completed the first two implants of the company’s C-Pulse heart assist system under a 20-person clinical trial approved by the U.S. Food and Drug Administration.
First Patient Successfully Treated With Algisyl-LVR Device
Symphony Medical, a developer of novel biopolymer technologies for cardiac disorders, has successfully used its flagship Algisyl-LVR technology to treat their first human patient.
GlaxoSmithKline, Pfizer Team Up Against HIV
The collaboration of two pharmaceutical giants may mark the beginning of an industry shift. Pfizer and GlaxoSmithKline are combining their HIV drug businesses into a single, jointly owned company that will account for almost 20 percent of the market.
NIH Proposal Expands Stem Cell Funding
Embryonic stem-cell research would get a financial boost under a new proposal by the National Institutes of Health. According to the Wall Street Journal, the NIH guidelines expand funding for cell lines derived from surplus human embryos.